December 10, 2020 -- Moderna has begun a late-stage trial for a COVID-19 vaccine for adolescents between 12 and 18 years of age. The vaccine is called messenger RNA (mRNA)-1273.
The study will include 3,000 participants and is being performed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The vaccine will be given twice, 28 days apart; each participant will receive either a placebo at each of these injections or a 100 µg dose of the vaccine. The trial will follow the study participants for 12 months after the second injection.
"Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," chief executive officer Stéphane Bancel said in a statement released by the firm.